Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Go back to Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 16.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.21 | 52 Week High | $0.19 | |||
| Open | $16.21 | 52 Week Low | $0.07 | |||
| Day High | $16.21 | P/E | N/A | |||
| Day Low | $16.21 | EPS | $-0.01 | |||
| Volume | 936 | |||||
